8-KRegulation FDExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Regulation FD Disclosure (Sep 25, 2013)

Filed September 25, 2013For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on September 25, 2013, reporting a significant financing event. The company announced it had priced and entered into an agreement to issue and sell $600 million aggregate principal amount of 2.875% senior unsecured notes due 2018. This action indicates the company's proactive approach to managing its capital structure and potentially funding future growth initiatives or refinancing existing debt. The issuance of these notes, detailed in a press release attached as an exhibit, provides insight into the company's access to capital markets. The relatively low interest rate of 2.875% suggests a favorable credit standing and market confidence in Edwards Lifesciences' financial health and future prospects at the time of the filing.

Key Highlights

  • 1Edwards Lifesciences priced and agreed to issue $600 million in senior unsecured notes.
  • 2The notes carry a coupon rate of 2.875%.
  • 3The maturity date for these notes is 2018.
  • 4The filing occurred on September 25, 2013, with the event date being September 24, 2013.
  • 5The issuance was conducted under an effective registration statement.
  • 6Merrill Lynch, Pierce, Fenner & Smith Incorporated and Goldman, Sachs & Co. acted as representatives of the underwriters.

Frequently Asked Questions

This 8-K filing is primarily to disclose that Edwards Lifesciences has priced and agreed to issue $600 million in senior unsecured notes due 2018. It also includes the press release announcing this transaction.

The notes are senior unsecured notes with an aggregate principal amount of $600 million, a fixed interest rate of 2.875%, and a maturity date of 2018.

This issuance suggests the company is actively managing its capital structure, potentially to fund operations, acquisitions, research and development, or to refinance existing debt. The favorable interest rate indicates a strong credit profile and confidence from investors in the company's financial stability.

Merrill Lynch, Pierce, Fenner & Smith Incorporated and Goldman, Sachs & Co. are acting as the representatives of the several underwriters for this offering.